APLP2

Across TCGA pan-cancer cohorts, APLP2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated APLP2 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher APLP2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated APLP2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, PRAD, and ESCA are the cancer types where APLP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.098	0.651	.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	.001	6	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
LUSC	OS	Median	All	0.005	0.762	<.001	6	view →
UCEC	DFS	Median	All	0.922	0.620	.026	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

APLP2–LUAD (DFS)

Open the LUAD breakdown →